Communication to the Editor
Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs
Conflict of interest statement: None declared.
ABSTRACT
Sickle cell disease (SCD) is the most common human genetic disease which is caused by a single mutation of human β‐globin (HBB) gene. The lack of long‐term treatment makes the development of reliable cell and gene therapies highly desirable. Disease‐specific patient‐derived human induced pluripotent stem cells (hiPSCs) have great potential for developing novel cell and gene therapies. With the disease‐causing mutations corrected in situ, patient‐derived hiPSCs can restore normal cell functions and serve as a renewable autologous cell source for the treatment of genetic disorders. Here we successfully utilized transcription activator‐like effector nucleases (TALENs), a recently emerged novel genome editing tool, to correct the SCD mutation in patient‐derived hiPSCs. The TALENs we have engineered are highly specific and generate minimal off‐target effects. In combination with piggyBac transposon, TALEN‐mediated gene targeting leaves no residual ectopic sequences at the site of correction and the corrected hiPSCs retain full pluripotency and a normal karyotype. Our study demonstrates an important first step of using TALENs for the treatment of genetic diseases such as SCD, which represents a significant advance toward hiPSC‐based cell and gene therapies. Biotechnol. Biotechnol. Bioeng. 2014;111: 1048–1053. © 2013 Wiley Periodicals, Inc.
Citing Literature
Number of times cited: 61
- Junaid Ansari, Youmna E Moufarrej, Rafal Pawlinski and Felicity N.E. Gavins, Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease, Expert Review of Hematology, 11, 1, (45), (2018).
- Constantinos C. Loucari, Petros Patsali, Thamar B. van Dijk, Coralea Stephanou, Panayiota Papasavva, Maria Zanti, Ryo Kurita, Yukio Nakamura, Soteroulla Christou, Maria Sitarou, Sjaak Philipsen, Carsten W. Lederer and Marina Kleanthous, Rapid and Sensitive Assessment of Globin Chains for Gene and Cell Therapy of Hemoglobinopathies, Human Gene Therapy Methods, 29, 1, (60), (2018).
- Duran Sürün, Joachim Schwäble, Ana Tomasovic, Roy Ehling, Stefan Stein, Nina Kurrle, Harald von Melchner and Frank Schnütgen, High Efficiency Gene Correction in Hematopoietic Cells by Donor-Template-Free CRISPR/Cas9 Genome Editing, Molecular Therapy - Nucleic Acids, 10, (1), (2018).
- Alexander Kondrashov, Minh Duc Hoang, James Smith, Jamie Bhagwan, Gary Duncan, Diogo Mosqueira, Maria Munoz, Nguyen T.N. Vo and Chris Denning, Simplified footprint-free Cas9/CRISPR editing of cardiac-associated genes in human pluripotent stem cells, Stem Cells and Development, (2018).
- Maria Rosa Lidonnici and Giuliana Ferrari, Gene therapy and gene editing strategies for hemoglobinopathies, Blood Cells, Molecules, and Diseases, (2018).
- Jaitip Tipanee, Yoke Chin Chai, Thierry VandenDriessche and Marinee K. Chuah, Preclinical and clinical advances in transposon-based gene therapy, Bioscience Reports, 10.1042/BSR20160614, 37, 6, (BSR20160614), (2017).
- Nicholas Brookhouser, Sreedevi Raman, Christopher Potts and David. Brafman, May I Cut in? Gene Editing Approaches in Human Induced Pluripotent Stem Cells, Cells, 6, 4, (5), (2017).
- Ehsan Maleki, Hossein Babashah, Somayyeh Koohi and Zahra Kavehvash, High-speed all-optical DNA local sequence alignment based on a three-dimensional artificial neural network, Journal of the Optical Society of America A, 34, 7, (1173), (2017).
- Sumitra Shankar, Deepti Prasad, Rahul Sanawar, Ani V. Das and M. Radhakrishna Pillai, TALEN based HPV-E7 editing triggers necrotic cell death in cervical cancer cells, Scientific Reports, 7, 1, (2017).
- Eun Ji Kim, Ki Ho Kang and Ji Hyeon Ju, CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells, The Korean Journal of Internal Medicine, 32, 1, (42), (2017).
- Ranjita Sengupta, Amy Mendenhall, Nandita Sarkar, Chandreyee Mukherjee, Amirali Afshari, Joseph Huang and Biao Lu, Viral Cre-LoxP tools aid genome engineering in mammalian cells, Journal of Biological Engineering, 11, 1, (2017).
- Alexandra Kuhn, Mania Ackermann, Claudio Mussolino, Toni Cathomen, Nico Lachmann and Thomas Moritz, TALEN-mediated functional correction of human iPSC-derived macrophages in context of hereditary pulmonary alveolar proteinosis, Scientific Reports, 7, 1, (2017).
- Jaitip Tipanee, Thierry VandenDriessche and Marinee K. Chuah, Transposons: Moving Forward from Preclinical Studies to Clinical Trials, Human Gene Therapy, 10.1089/hum.2017.128, 28, 11, (1087-1104), (2017).
- Bárbara Cristina Martins Fernandes Paes, Pablo Diego Moço, Cristiano Gonçalves Pereira, Geciane Silveira Porto, Elisa Maria de Sousa Russo, Luiza Cunha Junqueira Reis, Dimas Tadeu Covas and Virginia Picanço-Castro, Ten years of iPSC: clinical potential and advances in vitro hematopoietic differentiation, Cell Biology and Toxicology, 33, 3, (233), (2017).
- Yuanyuan Yang, Xiaobai Zhang, Li Yi, Zhenzhen Hou, Jiayu Chen, Xiaochen Kou, Yanhong Zhao, Hong Wang, Xiao-Fang Sun, Cizhong Jiang, Yixuan Wang and Shaorong Gao, Naïve Induced Pluripotent Stem Cells Generated From β‐Thalassemia Fibroblasts Allow Efficient Gene Correction With CRISPR/Cas9, STEM CELLS Translational Medicine, 5, 1, (8-19), (2015).
- Leif S. Ludwig, Rajiv K. Khajuria and Vijay G. Sankaran, Emerging cellular and gene therapies for congenital anemias, American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 172, 4, (332-348), (2016).
- M. D. Hoban, S. H. Orkin and D. E. Bauer, Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease, Blood, 10.1182/blood-2015-09-618587, 127, 7, (839-848), (2016).
- Michael A. Goodman and Punam Malik, The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges, Therapeutic Advances in Hematology, 7, 5, (302), (2016).
- M. C. Canver and S. H. Orkin, Customizing the genome as therapy for the -hemoglobinopathies, Blood, 127, 21, (2536), (2016).
- Yiren Qin and Wei‐Qiang Gao, Concise Review: Patient‐Derived Stem Cell Research for Monogenic Disorders, STEM CELLS, 34, 1, (44-54), (2015).
- S.D. Sackett, M.E. Brown, D.M. Tremmel, T. Ellis, W.J. Burlingham and J.S. Odorico, Modulation of human allogeneic and syngeneic pluripotent stem cells and immunological implications for transplantation, Transplantation Reviews, 30, 2, (61), (2016).
- M. D. Hoban and D. E. Bauer, A genome editing primer for the hematologist, Blood, 10.1182/blood-2016-01-678151, 127, 21, (2525-2535), (2016).
- Sylvia Merkert and Ulrich Martin, Targeted genome engineering using designer nucleases: State of the art and practical guidance for application in human pluripotent stem cells, Stem Cell Research, 16, 2, (377), (2016).
- Andrea Pellagatti, Hamid Dolatshad, Bon Ham Yip, Simona Valletta and Jacqueline Boultwood, Application of genome editing technologies to the study and treatment of hematological disease, Advances in Biological Regulation, 60, (122), (2016).
- Li B Li, Chao Ma, Geneve Awong, Marion Kennedy, German Gornalusse, Gordon Keller, Dan S Kaufman and David W Russell, Silent IL2RG Gene Editing in Human Pluripotent Stem Cells, Molecular Therapy, 24, 3, (582), (2016).
- Ganesan Govindan and Sivaprakash Ramalingam, Programmable Site‐Specific Nucleases for Targeted Genome Engineering in Higher Eukaryotes, Journal of Cellular Physiology, 231, 11, (2380-2392), (2016).
- Yoon-Young Jang and Zhaohui Ye, Gene correction in patient-specific iPSCs for therapy development and disease modeling, Human Genetics, 135, 9, (1041), (2016).
- Sylvia Merkert and Ulrich Martin, Site-Specific Genome Engineering in Human Pluripotent Stem Cells, International Journal of Molecular Sciences, 17, 12, (1000), (2016).
- Liuhong Cai, Yoon-Young Jang and Zhaohui Ye, Genome Editing in Human Pluripotent Stem Cells, Recent Advances in Stem Cells, 10.1007/978-3-319-33270-3_3, (43-67), (2016).
- Michele Lai, Massimo Pifferi, Andrew Bush, Martina Piras, Angela Michelucci, Maria Di Cicco, Ambra del Grosso, Paola Quaranta, Chiara Cursi, Elena Tantillo, Sara Franceschi, Maria Chiara Mazzanti, Paolo Simi, Giuseppe Saggese, Attilio Boner and Mauro Pistello, Gene editing of DNAH11 restores normal cilia motility in primary ciliary dyskinesia , Journal of Medical Genetics, 10.1136/jmedgenet-2015-103539, 53, 4, (242-249), (2016).
- Xiaohua Niu, Wenyin He, Bing Song, Zhanhui Ou, Di Fan, Yuchang Chen, Yong Fan and Xiaofang Sun, Combining Single Strand Oligodeoxynucleotides and CRISPR/Cas9 to Correct Gene Mutations in β-Thalassemia-induced Pluripotent Stem Cells, Journal of Biological Chemistry, 291, 32, (16576), (2016).
- M. A. DeWitt, W. Magis, N. L. Bray, T. Wang, J. R. Berman, F. Urbinati, S.-J. Heo, T. Mitros, D. P. Munoz, D. Boffelli, D. B. Kohn, M. C. Walters, D. Carroll, D. I. K. Martin and J. E. Corn, Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells, Science Translational Medicine, 8, 360, (360ra134), (2016).
- Versha Prakash, Marc Moore and Rafael J Yáñez-Muñoz, Current Progress in Therapeutic Gene Editing for Monogenic Diseases, Molecular Therapy, 24, 3, (465), (2016).
- Ipek Tasan, Surbhi Jain and Huimin Zhao, Use of genome-editing tools to treat sickle cell disease, Human Genetics, 10.1007/s00439-016-1688-0, 135, 9, (1011-1028), (2016).
- Han Zhang and Nami McCarty, CRISPR‐Cas9 technology and its application in haematological disorders, British Journal of Haematology, 175, 2, (208-225), (2016).
- Ayako Nishizawa‐Yokoi, Masaki Endo, Namie Ohtsuki, Hiroaki Saika and Seiichi Toki, Precision genome editing in plants via gene targeting and piggyac‐mediated marker excision, The Plant Journal, 81, 1, (160-168), (2014).
- Xiaosong Huang, Ying Wang, Wei Yan, Cory Smith, Zhaohui Ye, Jing Wang, Yongxing Gao, Laurel Mendelsohn and Linzhao Cheng, Production of Gene‐Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation, STEM CELLS, 33, 5, (1470-1479), (2015).
- Vijay G Sankaran and Mitchell J Weiss, Anemia: progress in molecular mechanisms and therapies, Nature Medicine, 21, 3, (221), (2015).
- Kristian Alsbjerg Skipper and Jacob Giehm Mikkelsen, Delivering the Goods for Genome Engineering and Editing, Human Gene Therapy, 10.1089/hum.2015.063, 26, 8, (486-497), (2015).
- M Kolot, N Malchin, A Elias, N Gritsenko and E Yagil, Site promiscuity of coliphage HK022 integrase as a tool for gene therapy, Gene Therapy, 22, 7, (521), (2015).
- M. D. Hoban, G. J. Cost, M. C. Mendel, Z. Romero, M. L. Kaufman, A. V. Joglekar, M. Ho, D. Lumaquin, D. Gray, G. R. Lill, A. R. Cooper, F. Urbinati, S. Senadheera, A. Zhu, P.-Q. Liu, D. E. Paschon, L. Zhang, E. J. Rebar, A. Wilber, X. Wang, P. D. Gregory, M. C. Holmes, A. Reik, R. P. Hollis and D. B. Kohn, Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells, Blood, 125, 17, (2597), (2015).
- Seahyoung Lee, Chang Yeon Lee, Jiyun Lee, Hyang-Hee Seo and Ki-Chul Hwang, Cut and paste the genome: Genome editing for research and therapy, Journal of Cellular Biotechnology, 1, 1, (95), (2015).
- Subin Raj Cheri Kunnumal Rajendran, Yuan-Yeu Yau, Dinesh Pandey and Anil Kumar, CRISPR-Cas9 Based Genome Engineering: Opportunities in Agri-Food-Nutrition and Healthcare, OMICS: A Journal of Integrative Biology, 19, 5, (261), (2015).
- Justin S. LaFountaine, Kristin Fathe and Hugh D.C. Smyth, Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9, International Journal of Pharmaceutics, 10.1016/j.ijpharm.2015.08.029, 494, 1, (180-194), (2015).
- Peng Xu, Ying Tong, Xiu-zhen Liu, Ting-ting Wang, Li Cheng, Bo-yu Wang, Xiang Lv, Yue Huang and De-pei Liu, Both TALENs and CRISPR/Cas9 directly target the HBB IVS2–654 (C > T) mutation in β-thalassemia-derived iPSCs, Scientific Reports, 5, 1, (2015).
- Takamasa Tobita, Jorge Guzman-Lepe and Alexandra Collin de l'Hortet, From hacking the human genome to editing organs, Organogenesis, 11, 4, (173), (2015).
- Hiroshi Ochiai, Single-Base Pair Genome Editing in Human Cells by Using Site-Specific Endonucleases, International Journal of Molecular Sciences, 16, 12, (21128), (2015).
- Lisa M. Ott de Bruin, Stefano Volpi and Kiran Musunuru, Novel Genome-Editing Tools to Model and Correct Primary Immunodeficiencies, Frontiers in Immunology, 6, (2015).
- Talita Giacomet de Carvalho, Ursula da Silveira Matte, Roberto Giugliani and Guilherme Baldo, Genome Editing: Potential Treatment for Lysosomal Storage Diseases, Current Stem Cell Reports, 10.1007/s40778-014-0007-8, 1, 1, (9-15), (2015).
- Justin S. Antony, Alexander Dewerth, Ashiqul Haque, Rupert Handgretinger and Michael S.D. Kormann, Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies, Molecular and Cellular Pediatrics, 2, 1, (2015).
- Sujal Ghosh, Adrian J. Thrasher and H. Bobby Gaspar, Gene therapy for monogenic disorders of the bone marrow, British Journal of Haematology, 171, 2, (155-170), (2015).
- Ning Sun, Zehua Bao, Xiong Xiong and Huimin Zhao, SunnyTALEN: A second‐generation TALEN system for human genome editing, Biotechnology and Bioengineering, 111, 4, (683-691), (2013).
- Tommaso Vannocci, Hitoshi Kurata, Josu Fuente, Irene A. Roberts and Andrew C. G. Porter, Nuclease‐stimulated homologous recombination at the human β‐globin gene, The Journal of Gene Medicine, 16, 1-2, (1-10), (2014).
- Ning Sun and Huimin Zhao, A single-chain TALEN architecture for genome engineering, Mol. BioSyst., 10.1039/C3MB70412B, 10, 3, (446-453), (2014).
- Alessia Finotti and Roberto Gambari, Recent trends for novel options in experimental biological therapy of β-thalassemia, Expert Opinion on Biological Therapy, 10.1517/14712598.2014.927434, 14, 10, (1443-1454), (2014).
- Kristine Freude, Carlota Pires, Poul Hyttel and Vanessa Hall, Induced Pluripotent Stem Cells Derived from Alzheimer’s Disease Patients: The Promise, the Hope and the Path Ahead, Journal of Clinical Medicine, 3, 4, (1402), (2014).
- Huen Suk Kim, Jeffrey M. Bernitz, Dung-Fang Lee and Ihor R. Lemischka, Genomic Editing Tools to Model Human Diseases with Isogenic Pluripotent Stem Cells, Stem Cells and Development, 23, 22, (2673), (2014).
- Claudio Mussolino, Jamal Alzubi, Eli J. Fine, Robert Morbitzer, Thomas J. Cradick, Thomas Lahaye, Gang Bao and Toni Cathomen, TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity, Nucleic Acids Research, 42, 10, (6762), (2014).
- Shanmuganathan Chandrakasan and Punam Malik, Gene Therapy for Hemoglobinopathies, Hematology/Oncology Clinics of North America, 28, 2, (199), (2014).
- J.-A. Talano and M. S. Cairo, Smoothing the crescent curve: sickle cell disease, Hematology, 2014, 1, (468), (2014).
- Michael A Goodman and Punam Malik, Gene Therapy for Haemoglobinopathies, eLS, (1-8), (2016).
